[1]	BR VK, SARIN SK. Acute-on-chronic liver failure: Terminology, mechanisms and management[J]. Clin Mol Hepatol, 2023, 29(3): 670-689. DOI: 10.3350/cmh.2022.0103. 本文引用 [1]

[2]	AGGARWAL A, BISWAS S, ARORA U, et al. Definitions, etiologies, and outcomes of acute on chronic liver failure: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2024, 22(11): 2199-2210. e25. DOI: 10.1016/j.cgh.2024.04.018. 本文引用 [2]

[3]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure[J]. Chin J Clin Infect Dis, 2008, 1(1): 47-53. DOI: 10.3760/cma.j.issn.1674-2397.2008.01.014. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病人工肝学组. 肝衰竭诊疗指南[J]. 中华临床感染病杂志, 2008, 1(1): 47-53. DOI: 10.3760/cma.j.issn.1674-2397.2008.01.014. 本文引用 [1]

[4]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2012) [J]. Chin J Clin Infect Dis, 2012, 5(6): 321-327. DOI: 10.3760/cma.j.issn.1674-2397.2012.06.001. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版)[J]. 中华临床感染病杂志, 2012, 5(6): 321-327. DOI: 10.3760/cma.j.issn.1674-2397.2012.06.001.

[5]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 本文引用 [2]

[6]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2024 version)[J]. J Clin Hepatol, 2024, 40(12): 2371-2387. DOI: 10.12449/JCH241206. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40(12): 2371-2387. DOI: 10.12449/JCH241206. 本文引用 [4]

[7]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. Chin J Hepatol, 2025, 33(4): 329-339. DOI: 10.3760/cma.j.cn501113-20250312-00089. 中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025年版) [J]. 中华肝脏病杂志, 2025, 33(4): 329-339. DOI: 10.3760/cma.j.cn501113-20250312-00089. 本文引用 [1]

[8]	OHNISHI H, SUGIHARA J, MORIWAKI H, et al. Acute-on-chronic liver failure[J]. Ryoikibetsu Shokogun Shirizu, 1995(7): 217-219. 本文引用 [1]

[9]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3. 本文引用 [2]

[10]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure[J]. J Hepatol, 2023, 79(2): 461-491. DOI: 10.1016/j.jhep.2023.04.021. 本文引用 [2]

[11]	BAJAJ JS, O’LEARY JG, REDDY KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures[J]. Hepatology, 2014, 60(1): 250-256. DOI: 10.1002/hep.27077. 本文引用 [1]

[12]	BAJAJ JS, O’LEARY JG, LAI JC, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117(2): 225-252. DOI: 10.14309/ajg.0000000000001595. 本文引用 [1]

[13]	KARVELLAS CJ, BAJAJ JS, KAMATH PS, et al. AASLD Practice Guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis[J]. Hepatology, 2024, 79(6): 1463-1502. DOI: 10.1097/HEP.0000000000000671. 本文引用 [1]

[14]	CHOUDHURY A, KULKARNI AV, ARORA V, et al. Acute-on-chronic liver failure (ACLF): The ‘Kyoto consensus’-steps from Asia[J]. Hepatol Int, 2025, 19(1): 1-69. DOI: 10.1007/s12072-024-10773-4. 本文引用 [1]

[15]	CLÀRIA J, ARROYO V, MOREAU R. Roles of systemic inflammatory and metabolic responses in the pathophysiology of acute-on-chronic liver failure[J]. JHEP Rep, 2023, 5(9): 100807. DOI: 10.1016/j.jhepr.2023.100807. 本文引用 [1]

[16]	ENGELMANN C, CLÀRIA J, SZABO G, et al. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. J Hepatol, 2021, 75(Suppl 1): S49-S66. DOI: 10.1016/j.jhep.2021.01.002.

[17]	SARIN SK, KEDARISETTY CK, ABBAS Z, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J]. Hepatol Int, 2014, 8(4): 453-471. DOI: 10.1007/s12072-014-9580-2. 本文引用 [1]

[18]

XU MM, LI SS, YANG YR, et al. Epidemiological characteristics of inpatients with liver failure at the Beijing You’an Hospital from 2012 to 2021[J]. Chin J Hepatol, 2024, 32(1): 49-57. DOI: 10.3760/cma.j.cn501113-20220824-00433. 徐曼曼, 李珊珊, 杨颜榕, 等. 2012至2021年北京佑安医院肝衰竭住院患者流行病学特征[J]. 中华肝脏病杂志, 2024, 32(1): 49-57. DOI: 10.3760/cma.j.cn501113-20220824-00433. 本文引用 [1]

[19]	XU MM, CHEN Y. New perspectives in the definition and classification of acute-on-chronic liver failure[J]. Chin Med J (Engl), 2024, 137(21): 2521-2525. DOI: 10.1097/CM9.0000000000003289. 本文引用 [1]

[20]	XU MM, KONG M, YU PF, et al. Clinical course and outcome patterns of acute-on-chronic liver failure: A multicenter retrospective cohort study[J]. J Clin Transl Hepatol, 2021, 9(5): 626-634. DOI: 10.14218/JCTH.2020.00179. 本文引用 [2]

[21]	SCHWARZ M, SIMBRUNNER B, JACHS M, et al. High histamine levels are associated with acute-on-chronic liver failure and liver-related death in patients with advanced chronic liver disease[J]. Liver Int, 2024, 44(11): 2904-2914. DOI: 10.1111/liv.16056. 本文引用 [1]

[22]	MO RD, ZHANG ZL, ZHOU YM, et al. A new prognostic model based on serum apolipoprotein AI in patients with HBV-ACLF and acutely decompensated liver cirrhosis[J]. Lipids Health Dis, 2025, 24(1): 35. DOI: 10.1186/s12944-025-02434-8.

[23]	ZHANG Y, TAN WT, WANG XB, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79(5): 1159-1171. DOI: 10.1016/j.jhep.2023.07.011.

[24]	HU CH, JIANG N, ZHENG J, et al. Liver volume based prediction model for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatobiliary Pancreat Sci, 2022, 29(12): 1253-1263. DOI: 10.1002/jhbp.1112. 本文引用 [1]

[25]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172. 本文引用 [1]

[26]	KIM WR, BIGGINS SW, KREMERS WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list[J]. N Engl J Med, 2008, 359(10): 1018-1026. DOI: 10.1056/NEJMoa0801209. 本文引用 [1]

[27]	JALAN R, SALIBA F, PAVESI M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure[J]. J Hepatol, 2014, 61(5): 1038-1047. DOI: 10.1016/j.jhep.2014.06.012. 本文引用 [1]

[28]	LI JQ, LIANG X, YOU SL, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatol, 2021, 75(5): 1104-1115. DOI: 10.1016/j.jhep.2021.05.026. 本文引用 [1]

[29]	CHOUDHURY A, JINDAL A, MAIWALL R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): Comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models[J]. Hepatol Int, 2017, 11(5): 461-471. DOI: 10.1007/s12072-017-9816-z. 本文引用 [1]

[30]	O’LEARY JG, REDDY KR, GARCIA-TSAO G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis[J]. Hepatology, 2018, 67(6): 2367-2374. DOI: 10.1002/hep.29773. 本文引用 [1]

[31]	GUSTOT T, FERNANDEZ J, GARCIA E, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis[J]. Hepatology, 2015, 62(1): 243-252. DOI: 10.1002/hep.27849. 本文引用 [1]

[32]	YU ZJ, ZHANG Y, CAO YY, et al. A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators[J]. Sci Rep, 2021, 11(1): 1810. DOI: 10.1038/s41598-021-81431-0. 本文引用 [1]

[33]	MENG QH, HOU W, YU HW, et al. Resting energy expenditure and substrate metabolism in patients with acute-on-chronic hepatitis B liver failure[J]. J Clin Gastroenterol, 2011, 45(5): 456-461. DOI: 10.1097/MCG.0b013e31820f7f02. 本文引用 [1]

[34]	CHEUNG K, LEE SS, RAMAN M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies[J]. Clin Gastroenterol Hepatol, 2012, 10(2): 117-125. DOI: 10.1016/j.cgh.2011.08.016.

[35]

Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010. 中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 临床肝胆病杂志, 2019, 35(6): 1222-1230. DOI: 10.3969/j.issn.1001-5256.2019.06.010. 本文引用 [1]

[36]	YAO J, ZHOU XS, WANG H, et al. Persistently increased resting energy expenditure predicts short-term mortality in patients with acute-on-chronic liver failure[J]. Ann Nutr Metab, 2018, 73(1): 2-9. DOI: 10.1159/000487604. 本文引用 [1]

[37]	LIU X, KONG M, HUA X, et al. Effects of an individualized nutritional intervention on the prognosis of patients with liver failure[J]. Asia Pac J Clin Nutr, 2022, 31(2): 215-221. DOI: 10.6133/apjcn.202206_31(2).0007.

[38]	KUMAR R, PRAKASH SS, PRIYADARSHI RN, et al. Sarcopenia in chronic liver disease: A metabolic perspective[J]. J Clin Transl Hepatol, 2022, 10(6): 1213-1222. DOI: 10.14218/JCTH.2022.00239. 本文引用 [1]

[39]	GREGORY PB, KNAUER CM, KEMPSON RL, et al. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo[J]. N Engl J Med, 1976, 294(13): 681-687. DOI: 10.1056/NEJM197603252941301. 本文引用 [1]

[40]	FUJIWARA K, YASUI S, HAGA Y, et al. Early combination therapy with corticosteroid and nucleoside analogue induces rapid resolution of inflammation in acute liver failure due to transient hepatitis B virus infection[J]. Intern Med, 2018, 57(11): 1543-1552. DOI: 10.2169/internalmedicine.9670-17.

[41]	ZHAO J, ZHANG JY, YU HW, et al. Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy[J]. Cell Mol Immunol, 2012, 9(5): 417-422. DOI: 10.1038/cmi.2011.51.

[42]	HUANG C, YU KK, ZHENG JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: A 10-year cohort study in a university hospital in East China[J]. J Dig Dis, 2019, 20(1): 38-44. DOI: 10.1111/1751-2980.12691.

[43]	JIA L, XUE R, ZHU YK, et al. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: A prospective multi-center clinical trial[J]. BMC Med, 2020, 18(1): 383. DOI: 10.1186/s12916-020-01814-4. 本文引用 [2]

[44]	XUE R, MENG QH. The management of glucocorticoid therapy in liver failure[J]. Front Immunol, 2019, 10: 2490. DOI: 10.3389/fimmu.2019.02490. 本文引用 [1]

[45]	ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2020, 3(1): 100176. DOI: 10.1016/j.jhepr.2020.100176.

[46]	CASULLERAS M, ZHANG IW, LÓPEZ-VICARIO C, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells, 2020, 9(12): 2632. DOI: 10.3390/cells9122632.

[47]	CHEN P, WANG YY, CHEN C, et al. The immunological roles in acute-on-chronic liver failure: An update[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(5): 403-411. DOI: 10.1016/j.hbpd.2019.07.003. 本文引用 [1]

[48]	XU Y, JIANG YF, LI Y. Outcomes of glucocorticoid treatment in HBVAssociated acute-on-chronic liver failure patients: A retrospective observational study[J]. Turk J Gastroenterol, 2021, 32(5): 473-480. DOI: 10.5152/tjg.2021.20257. 本文引用 [1]

[49]	WU ZB, WANG K, MO ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure[J]. Clin Res Hepatol Gastroenterol, 2021, 45(5): 101505. DOI: 10.1016/j.clinre.2020.07.010.

[50]	SHI P, ZHU WT, LIANG A, et al. Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Acta Gastroenterol Belg, 2022, 85(4): 593-600. DOI: 10.51821/85.4.10728. 本文引用 [1]

[51]

Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification (2022 edition)[J]. J Clin Hepatol, 2022, 38(4): 767-775. DOI: 10.3969/j.issn.1001-5256.2022.04.007. 中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38(4): 767-775. DOI: 10.3969/j.issn.1001-5256.2022.04.007. 本文引用 [1]

[52]	OCAK I. A 15-year retrospective study of supportive extracorporeal therapies including plasma exchange and continuous venovenous hemodiafiltration of 114 adults with acute liver failure awaiting liver transplantation[J]. Ann Transplant, 2023, 28: e939745. DOI: 10.12659/AOT.939745.

[53]	WANG L, XU WX, ZHU S, et al. Double plasma molecular adsorption system with sequential low-dose plasma exchange in patients with hepatitis B virus-related acute-on-chronic liver failure: A prospective study[J]. J Clin Transl Hepatol, 2023, 11(4): 908-917. DOI: 10.14218/JCTH.2022.00254.

[54]	XU WX, ZHU S, YANG L, et al. Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure[J]. J Med Virol, 2023, 95(3): e28650. DOI: 10.1002/jmv.28650.

[55]	MAIWALL R, BAJPAI M, SINGH A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: A randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2022, 20(4): e831-e854. DOI: 10.1016/j.cgh.2021.01.036.

[56]	HIRANO R, NAMAZUDA K, HIRATA N. Double filtration plasmapheresis: Review of current clinical applications[J]. Ther Apher Dial, 2021, 25(2): 145-151. DOI: 10.1111/1744-9987.13548.

[57]	LIU H, ZHANG Q, LIU L, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Artif Organs, 2020, 44(10): E434-E447. DOI: 10.1111/aor.13710.

[58]	YAO J, LI S, ZHOU L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34(4): 392-398. DOI: 10.1002/jca.21690. 本文引用 [1]

[59]

ZHOU L, CHEN Y. Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure[J]. Chin J Hepatol, 2022, 30(2): 127-130. DOI: 10.3760/cma.j.cn501113-20220108-00008. 周莉, 陈煜. 人工肝治疗肝衰竭模式选择及其疗效判断标准[J]. 中华肝脏病杂志, 2022, 30(2): 127-130. DOI: 10.3760/cma.j.cn501113-20220108-00008. 本文引用 [1]